General Pharmacology Practice Questions

Q: Which fully humanized antibody is used in treatment of rheumatoid arthritis?

Adalimumab. ***Adalimumab*** - **Adalimumab** is a **fully human monoclonal antibody** that targets **tumor necrosis factor-alpha (TNF-α)**, making it suitable for treating autoimmune conditions like rheumatoid arthritis without causing significant immunogenic reactions. - Its humanized structure minimizes the risk of developing **anti-drug antibodies**, improving long-term efficacy and safety. *Anakinra* - **Anakinra** is a **recombinant human interleukin-1 (IL-1) receptor antagonist**, not a fully humanized antibody. - While used in rheumatoid arthritis, its mechanism of action and structural classification differ from a fully humanized antibody. *Infliximab* - **Infliximab** is a **chimeric monoclonal antibody** (mouse-human), meaning it contains both mouse and human protein components. - It targets **TNF-α** but is not fully humanized, increasing the potential for immunogenicity compared to fully human antibodies. *Leflunomide* - **Leflunomide** is a **pyrimidine synthesis inhibitor**, functioning as an immunosuppressant rather than an antibody. - It works by inhibiting dihydroorotate dehydrogenase, which reduces lymphoid proliferation, making it a **disease-modifying antirheumatic drug (DMARD)**, not a biologic agent.

Q: Reason for preferring Cisatracurium over Atracurium is:-

Lesser provocation of histamine release. ***Lesser provocation of histamine release*** - **Cisatracurium** is preferred over atracurium primarily due to its significantly **lower potential to induce histamine release**, leading to fewer cardiovascular side effects like hypotension and tachycardia. - This property makes cisatracurium a **safer option** for patients prone to hemodynamic instability or allergic reactions. *Faster acting than Atracurium* - Both atracurium and cisatracurium are **intermediate-acting** neuromuscular blockers, and their onset times are quite similar, with cisatracurium sometimes having a slightly *slower* onset. - The difference in onset time is **not clinically significant** enough to be a primary reason for preference. *Shorter action than Atracurium* - **Cisatracurium** has a slightly **longer duration of action** compared to atracurium, although both are considered intermediate-acting drugs. - Therefore, a shorter duration of action is **not a reason for its preference**; instead, it might even be a slight disadvantage in certain clinical scenarios requiring rapid reversal. *Does not undergo Hoffman elimination* - Both atracurium and cisatracurium undergo **Hoffman elimination** (non-enzymatic degradation) and ester hydrolysis, which allows for their use in patients with renal or hepatic dysfunction. - This is a shared characteristic, not a distinguishing factor that makes cisatracurium superior, and cisatracurium actually relies *more* heavily on Hoffman elimination.

Q: 'Store in a cool place' is written on a drug label. It means drug should be stored at a temperature of:

8-15 degree Celsius. ***8-15 degree Celsius*** - According to **USP (United States Pharmacopeia)** and **IP (Indian Pharmacopoeia)** guidelines, "store in a **cool place**" specifically refers to a temperature range between **8 and 15 degrees Celsius**. - This is distinct from refrigeration and is suitable for medications that require cooler storage than room temperature but should not be refrigerated. - This temperature range helps maintain the **stability** and **efficacy** of temperature-sensitive medications. *2-8 degree Celsius* - This temperature range defines **"refrigeration"** or storage in a **"cold place"**, not a "cool place." - Refrigeration is indicated by the specific instruction "Store in refrigerator" or "Keep refrigerated" on drug labels. - Many biologics, vaccines, and insulin preparations require refrigeration at this temperature. *0 degree Celsius* - This temperature is the **freezing point of water**, and storing drugs at this temperature could lead to freezing, which can damage the drug's formulation. - Frozen medications may undergo **physical or chemical degradation**, particularly if they are aqueous solutions. - This is not indicated by "cool place" storage instructions. *-2 degree Celsius* - This temperature indicates storing the drug **below freezing**, which is only appropriate for specific **frozen products** with explicit freezing instructions. - **Freezing** can irreversibly alter the drug's structure, potentially affecting its safety and effectiveness. - This is well outside the range for "cool place" storage.

Q: How does the immunomodulatory effect of corticosteroids contribute to their role in the treatment of severe COVID-19?

Suppresses cytokine storm, reducing inflammation. ***Suppresses cytokine storm, reducing inflammation*** - Corticosteroids like **dexamethasone** are potent anti-inflammatory agents that reduce the production and activity of various **pro-inflammatory cytokines** (e.g., IL-6, TNF-α) central to the **cytokine storm** in severe COVID-19. - By dampening this excessive immune response, corticosteroids mitigate **acute respiratory distress syndrome (ARDS)** and systemic organ damage, thereby improving survival. *Enhances antibody production against the virus* - Corticosteroids are **immunosuppressive** and generally *reduce* antibody production, rather than enhancing it. - Their primary benefit in COVID-19 is related to controlling hyperinflammation, not bolstering the adaptive immune response. *Directly inhibits viral replication* - Corticosteroids do not possess direct antiviral properties; they do not target or inhibit the **severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)** replication cycle. - Antiviral medications, such as remdesivir, are designed for direct viral inhibition. *Increases ACE2 receptor expression, potentially facilitating viral entry* - There is no evidence to suggest that corticosteroids significantly increase **ACE2 receptor expression** in a manner that would facilitate viral entry in COVID-19 patients. - While immune responses can influence cellular receptor expression, the therapeutic benefit of corticosteroids in severe COVID-19 outweighs any theoretical concern regarding ACE2.

Q: What is the primary purpose of Phase III clinical trials for a new antihypertensive drug?

Evaluate the drug's efficacy and monitor side effects. **Evaluate the drug's efficacy and monitor side effects** - **Phase III trials** are designed to confirm the drug's effectiveness and safety in a large patient population, comparing it to standard treatments or placebo. - This phase aims to gather comprehensive data on **efficacy** and identify **rare or long-term side effects** that may not have been observed in earlier phases. *Determine the drug's safety profile* - While safety is continuously monitored throughout all phases, the primary focus on detailed **safety profiling** for rare adverse events often takes place during **Phase III** due to the larger sample size. - However, initial assessment of **basic safety and tolerability** is performed in **Phase I and II**. *Assess pharmacokinetics and pharmacodynamics* - **Pharmacokinetics (PK)**, which describes how the body affects the drug (absorption, distribution, metabolism, excretion), and **pharmacodynamics (PD)**, which describes how the drug affects the body, are primarily assessed in **Phase I** trials. - This early assessment helps determine optimal dosing and administration routes. *Test the drug in a small group of healthy volunteers* - This description best fits **Phase I clinical trials**, where a new drug is initially tested in a small group of **healthy volunteers** to assess its safety, dosage, and pharmacokinetics. - The goal is to determine if the drug is safe enough for further testing in patients.

Q: Which of the following drugs is LEAST likely to be delivered via a liposome drug delivery system?

Hyoscine. ***Hyoscine*** - **Hyoscine** (scopolamine) is a **small, lipid-soluble anticholinergic molecule** that readily crosses cell membranes and the blood-brain barrier due to its high **lipophilicity**. - Its excellent **oral and transdermal bioavailability** and ability to reach target tissues without assistance make liposomal encapsulation unnecessary and clinically redundant. - Unlike the other drugs listed, hyoscine does **not suffer from dose-limiting toxicity** that would benefit from targeted delivery. *Amphotericin B* - **Amphotericin B** is a potent **antifungal agent** with severe dose-limiting **nephrotoxicity** and infusion-related reactions. - **Liposomal formulations (AmBisome®)** are FDA-approved and widely used to significantly **reduce nephrotoxicity** while maintaining antifungal efficacy. - The liposomal delivery alters tissue distribution, reducing kidney exposure while enhancing accumulation in target tissues. *Vincristine* - **Vincristine** is a **vinca alkaloid chemotherapy agent** with dose-limiting **neurotoxicity** and poor tumor penetration. - **Liposomal vincristine (Marqibo®)** is FDA-approved and provides **prolonged circulation time**, enhanced tumor delivery, and reduced neurotoxicity. - The encapsulation improves the therapeutic index by increasing drug concentration at tumor sites. *Amikacin* - **Amikacin** is an **aminoglycoside antibiotic** with significant **nephrotoxicity and ototoxicity** that limit systemic dosing. - **Liposomal amikacin (Arikayce®)** is FDA-approved for mycobacterial lung infections, allowing **targeted pulmonary delivery** with reduced systemic exposure. - The formulation enables higher local drug concentrations with improved safety profile.

Q: What is the active principle of the plant Calotropis?

Calotropin. ***Calotropin*** - **Calotropin** is the primary **cardiac glycoside** found in the latex of the *Calotropis* plant, responsible for its toxic and medicinal properties. - This compound exerts its effects by inhibiting the **Na+/K+-ATPase pump**, leading to increased intracellular calcium and potentially cardiotoxicity. *Plumbagin* - **Plumbagin** is a **naphthoquinone** derivative found in plants like *Plumbago zeylanica*, known for its antimicrobial and anticancer activities. - It is not associated with *Calotropis* and has a different chemical structure and mechanism of action compared to cardiac glycosides. *Ricin* - **Ricin** is a highly potent **protein toxin** derived from the seeds of the **castor bean plant** (*Ricinus communis*). - Its mechanism involves inhibiting protein synthesis, which is distinct from the cardiac glycoside action of *Calotropis*. *Emodin* - **Emodin** is an **anthraquinone** derivative commonly found in plants such as **rhubarb** and **aloe**, known for its laxative and anti-inflammatory properties. - It is structurally and functionally different from the cardiac glycosides found in *Calotropis*.

Q: Depot preparations are administered by ?

Both subcutaneous and intramuscular route. ***Both subcutaneous and intramuscular route*** - **Depot preparations** are designed for **sustained release** of medication over an extended period - This is achieved by forming a 'depot' in the tissue, often facilitated by a viscous vehicle or sparingly soluble form of the drug - Both **subcutaneous** and **intramuscular** tissues can sustain depot formulations effectively - **SC depot examples:** Insulin glargine, contraceptive implants (Nexplanon), leuprolide acetate - **IM depot examples:** Haloperidol decanoate, medroxyprogesterone acetate (Depo-Provera), paliperidone palmitate, long-acting risperidone *Subcutaneous route* - While some **depot preparations** are administered **subcutaneously**, it is not the *only* route for all depot formulations - The **subcutaneous tissue** offers relatively low blood flow, suitable for slow absorption - Alone, this option is incomplete as many depot preparations require IM administration *Intramuscular route* - Many **depot preparations** are given **intramuscularly** due to the muscle tissue's vascularity and tissue volume - The **muscle tissue** provides an excellent site for drug reservoir formation - Alone, this option is incomplete as some depot preparations are given subcutaneously *Intravenous route* - **Intravenous administration** is used for immediate and rapid drug delivery directly into the bloodstream - This route is **unsuitable for depot preparations** which require sustained release over time - No 'depot' can be formed with IV route as the drug is immediately diluted and distributed throughout the body

Q: Most effective agent to prevent motion sickness is?

Hyoscine. ***Hyoscine*** - **Hyoscine (scopolamine)** is an anticholinergic drug that works by blocking muscarinic receptors in the **vestibular system** and **vomiting center**, making it highly effective for preventing motion sickness [1], [2]. - It is often administered as a **transdermal patch** for sustained release, providing convenience and prolonged efficacy [1], [2]. *Ephedrine* - **Ephedrine** is a sympathomimetic drug primarily used as a decongestant and bronchodilator. - While it has some central nervous system effects, it is **not considered a primary or effective agent** for preventing motion sickness. *Nedocromil* - **Nedocromil** is a mast cell stabilizer used in the treatment of asthma and allergic conjunctivitis. - Its mechanism of action involves **inhibiting the release of inflammatory mediators**, which is unrelated to the physiological pathways of motion sickness. *Cyproheptidine* - **Cyproheptidine** is a first-generation antihistamine with anticholinergic and antiserotonergic properties. - While some antihistamines can relieve motion sickness, cyproheptidine is mainly used for **allergic conditions** and as an **appetite stimulant**, and is not the most effective choice for motion sickness prevention [3].

Q: Which among the following is most probable reason for preference of Cisatracurium over atracurium?

Decreased histamine release. ***Decreased histamine release*** - **Cisatracurium** is preferred over atracurium primarily due to its significantly **lower potential for histamine release**, which can cause undesirable side effects like **hypotension**, **tachycardia**, and **bronchospasm**. - This reduced histamine release contributes to a **more stable hemodynamic profile** and **fewer allergic-type reactions**, especially in critically ill or hemodynamically unstable patients. *Increased histamine release* - This is incorrect because **atracurium** is known to cause **more histamine release** compared to cisatracurium, which is why cisatracurium is often preferred. - Increased histamine release is an **undesirable effect** that can lead to adverse cardiovascular and respiratory reactions. *Decreased CNS toxicity* - While both drugs are **quaternary ammonium compounds** and do not readily cross the blood-brain barrier, **CNS toxicity** is not a primary concern or differentiating factor between atracurium and cisatracurium in clinical practice. - The potential for CNS effects from their metabolites (like **laudanosine**) is generally low with standard dosing, and **cisatracurium produces less laudanosine**. *Due to elimination by non-specific plasma esterases* - Both cisatracurium and atracurium are eliminated primarily by **Hofmann elimination** and **non-specific plasma esterases**. This is a shared characteristic, not a reason for cisatracurium's preference over atracurium. - **Hofmann elimination** is a non-enzymatic chemical degradation process that occurs at physiological pH and temperature, making their elimination **independent of renal or hepatic function**.

Question 1

Which fully humanized antibody is used in treatment of rheumatoid arthritis?

Accepted Answer

Adalimumab

Answer

Anakinra

Answer

Infliximab

Answer

Leflunomide

Question 2

Reason for preferring Cisatracurium over Atracurium is:-

Accepted Answer

Lesser provocation of histamine release

Answer

Faster acting than Atracurium

Answer

Shorter action than Atracurium

Answer

Does not undergo Hoffman elimination

Question 3

'Store in a cool place' is written on a drug label. It means drug should be stored at a temperature of:

Accepted Answer

8-15 degree Celsius

Answer

0 degree Celsius

Answer

2-8 degree Celsius

Answer

-2 degree Celsius

Question 4

How does the immunomodulatory effect of corticosteroids contribute to their role in the treatment of severe COVID-19?

Accepted Answer

Suppresses cytokine storm, reducing inflammation

Answer

Enhances antibody production against the virus

Answer

Directly inhibits viral replication

Answer

Increases ACE2 receptor expression, potentially facilitating viral entry

Question 5

What is the primary purpose of Phase III clinical trials for a new antihypertensive drug?

Accepted Answer

Evaluate the drug's efficacy and monitor side effects

Answer

Determine the drug's safety profile

Answer

Assess pharmacokinetics and pharmacodynamics

Answer

Test the drug in a small group of healthy volunteers

Question 6

Which of the following drugs is LEAST likely to be delivered via a liposome drug delivery system?

Accepted Answer

Hyoscine

Answer

Amphotericin B

Answer

Vincristine

Answer

Amikacin

Question 7

What is the active principle of the plant Calotropis?

Accepted Answer

Calotropin

Answer

Emodin

Answer

Ricin

Answer

Plumbagin

Question 8

Depot preparations are administered by ?

Accepted Answer

Both subcutaneous and intramuscular route

Answer

Subcutaneous route

Answer

Intravenous route

Answer

Intramuscular route

Question 9

Most effective agent to prevent motion sickness is?

Accepted Answer

Hyoscine

Answer

Ephedrine

Answer

Nedocromil

Answer

Cyproheptidine

Question 10

Which among the following is most probable reason for preference of Cisatracurium over atracurium?

Accepted Answer

Decreased histamine release

Answer

Increased histamine release

Answer

Decreased CNS toxicity

Answer

Due to elimination by non-specific plasma esterases

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?